Start: July 22, 2021
End: February 28, 2023
Enrollment: 40
This Phase 1/2 study will assess the safety and effects of the experimental drug pepinemab, a monoclonal antibody treatment designed to improve memory, in older adults with early-stage Alzheimer's. Participants will be randomly assigned to receive either the study drug or a placebo by IV infusion once a month for one year. Throughout the trial, participants will undergo PET and MRI brain imaging, complete memory tests, and provide blood and spinal fluid samples. Researchers will monitor all participants for safety and any side effects throughout the trial and one month after the last treatment.
Minimum Age: 55 Years
Maximum Age: 85 Years
Contact study personnel listed either under the general study contact or the location nearest you.
Contact NIA’s Alzheimer’s and related Dementias Education and Referral (ADEAR) Center at 800-438-4380 or email ADEAR.
California | |
---|---|
Pacific Research Network, Inc
San Diego, CA 92103
Recruiting
Dixie Creager |
|
District of Columbia | |
Georgetown University
Washington, DC 20057
Recruiting
Robin Bean |
|
Florida | |
Brain Matters Research
Delray Beach, FL 33445
Recruiting
Mark Brody, MD |
|
Neuropsychiatric Research Center of Southwest Florida
Fort Myers, FL 33912
Recruiting
Melissa Schaerf |
|
JEM Research Institute
Lake Worth, FL 33462
Recruiting
Jayne Drew |
|
Brain Matters Research
Stuart, FL 34997
Recruiting
Mark Brody, MD |
|
Indiana | |
Indiana University School of Medicine
Indianapolis, IN 46202
Recruiting
Kala Hall |
|
Kansas | |
University of Kansas Medical Center
Fairway, KS 66205
Recruiting
Rebecca Bothwell |
|
New York | |
Columbia University Irving Medical Center
New York, NY 10032
Recruiting
Katrina Cuasay |
|
University of Rochester Medical Center
Rochester, NY 14620
Recruiting
Susan Salem-Spencer |
|
Virginia | |
Re-Cognition Health
Fairfax, VA 22031
Recruiting
Monica Bland |
Lead: Vaccinex Inc.
Collaborator Sponsor
Source: ClinicalTrials.gov ID: NCT04381468